These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 33956387)

  • 1. Short-term intensive insulin as induction and maintenance therapy for the preservation of beta-cell function in early type 2 diabetes (RESET-IT Main): A 2-year randomized controlled trial.
    Retnakaran R; Emery A; Ye C; Harris SB; Reichert SM; McInnes N; Gerstein HC; Thorpe KE; Kramer CK; Zinman B
    Diabetes Obes Metab; 2021 Aug; 23(8):1926-1935. PubMed ID: 33956387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-year trial of intermittent insulin therapy vs metformin for the preservation of β-cell function after initial short-term intensive insulin induction in early type 2 diabetes.
    Retnakaran R; Choi H; Ye C; Kramer CK; Zinman B
    Diabetes Obes Metab; 2018 Jun; 20(6):1399-1407. PubMed ID: 29377408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. INTERMITTENT INTENSIVE INSULIN THERAPY FOR TYPE 2 DIABETES: EFFECTS ON HYPOGLYCEMIA, WEIGHT GAIN, AND QUALITY OF LIFE OVER 2 YEARS.
    Emery A; Ye C; Choi H; Kramer CK; Zinman B; Retnakaran R
    Endocr Pract; 2019 Sep; 25(9):899-907. PubMed ID: 31170361
    [No Abstract]   [Full Text] [Related]  

  • 4. Determinants of reversibility of β-cell dysfunction in response to short-term intensive insulin therapy in patients with early type 2 diabetes.
    Kramer CK; Choi H; Zinman B; Retnakaran R
    Am J Physiol Endocrinol Metab; 2013 Dec; 305(11):E1398-407. PubMed ID: 24129396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial.
    Retnakaran R; Kramer CK; Choi H; Swaminathan B; Zinman B
    Diabetes Care; 2014 Dec; 37(12):3270-8. PubMed ID: 25249651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycemic variability in patients with early type 2 diabetes: the impact of improvement in β-cell function.
    Kramer CK; Choi H; Zinman B; Retnakaran R
    Diabetes Care; 2014 Apr; 37(4):1116-23. PubMed ID: 24550219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Short-term Intensive Insulin Therapy on Post-challenge Hyperglucagonemia in Early Type 2 Diabetes.
    Kramer CK; Zinman B; Choi H; Retnakaran R
    J Clin Endocrinol Metab; 2015 Aug; 100(8):2987-95. PubMed ID: 26079776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of short-term intensive insulin therapy on the incretin response in early type 2 diabetes.
    Choi H; Kramer CK; Zinman B; Connelly PW; Retnakaran R
    Diabetes Metab; 2019 Apr; 45(2):197-200. PubMed ID: 29395808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement in insulin sensitivity following intensive insulin therapy and association of glucagon with long-term diabetes remission.
    Zhang B; Chen YY; Yang ZJ; Wang X; Li GW
    J Int Med Res; 2016 Dec; 44(6):1543-1550. PubMed ID: 27834301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A two year observational study of nicotinamide and intensive insulin therapy in patients with recent onset type 1 diabetes mellitus.
    Crinó A; Schiaffini R; Ciampalini P; Suraci MC; Manfrini S; Visalli N; Matteoli MC; Patera P; Buzzetti R; Guglielmi C; Spera S; Costanza F; Fioriti E; Pitocco D; Pozzilli P;
    J Pediatr Endocrinol Metab; 2005 Aug; 18(8):749-54. PubMed ID: 16200840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How does blood glucose control with metformin influence intensive insulin protocols? Evidence for involvement of oxidative stress and inflammatory cytokines.
    Ansari G; Mojtahedzadeh M; Kajbaf F; Najafi A; Khajavi MR; Khalili H; Rouini MR; Ahmadi H; Abdollahi M
    Adv Ther; 2008 Jul; 25(7):681-702. PubMed ID: 18636232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of sustained drug-free diabetes remission over 48 weeks following short-term intensive insulin therapy in early type 2 diabetes.
    Kramer CK; Zinman B; Choi H; Retnakaran R
    BMJ Open Diabetes Res Care; 2016; 4(1):e000270. PubMed ID: 27547422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensive versus conventional insulin therapy in type 2 diabetes patients undergoing D2 gastrectomy for gastric cancer: a randomized controlled trial.
    Cao SG; Ren JA; Shen B; Chen D; Zhou YB; Li JS
    World J Surg; 2011 Jan; 35(1):85-92. PubMed ID: 20878324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The response to short-term intensive insulin therapy in type 2 diabetes.
    Retnakaran R; Yakubovich N; Qi Y; Opsteen C; Zinman B
    Diabetes Obes Metab; 2010 Jan; 12(1):65-71. PubMed ID: 19740080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of short-term intensive insulin therapy on quality of life in type 2 diabetes.
    Opsteen C; Qi Y; Zinman B; Retnakaran R
    J Eval Clin Pract; 2012 Apr; 18(2):256-61. PubMed ID: 20846320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
    Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
    Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting and understanding the response to short-term intensive insulin therapy in people with early type 2 diabetes.
    Nunez Lopez YO; Retnakaran R; Zinman B; Pratley RE; Seyhan AA
    Mol Metab; 2019 Feb; 20():63-78. PubMed ID: 30503831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes.
    Gastaldelli A; Nauck MA; Balena R
    Metabolism; 2013 Sep; 62(9):1330-9. PubMed ID: 23831441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weight loss and β-cell responses following gastric banding or pharmacotherapy in adults with impaired glucose tolerance or type 2 diabetes: a randomized trial.
    Utzschneider KM; Ehrmann DA; Arslanian SA; Barengolts E; Buchanan TA; Caprio S; Edelstein SL; Hannon TS; Kahn SE; Kozedub A; Mather KJ; Nadeau KJ; Sam S; Tripputi M; Xiang AH; El Ghormli L;
    Obesity (Silver Spring); 2022 Aug; 30(8):1579-1588. PubMed ID: 35894078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes.
    RISE Consortium
    Diabetes Care; 2019 Sep; 42(9):1742-1751. PubMed ID: 31178434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.